Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EBITDA: 2016-2025

Historic EBITDA for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to -$52.2 million.

  • Rocket Pharmaceuticals' EBITDA rose 24.74% to -$52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.5 million, marking a year-over-year increase of 8.51%. This contributed to the annual value of -$273.2 million for FY2024, which is 5.22% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' EBITDA stood at -$52.2 million, which was up 26.57% from -$71.1 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' EBITDA registered a high of -$34.0 million during Q2 2021, and its lowest value of -$73.7 million during Q2 2024.
  • Over the past 3 years, Rocket Pharmaceuticals' median EBITDA value was -$65.4 million (recorded in 2023), while the average stood at -$65.5 million.
  • The largest annual percentage gain for Rocket Pharmaceuticals' EBITDA in the last 5 years was 25.16% (2021), contrasted with its biggest fall of 81.28% (2021).
  • Rocket Pharmaceuticals' EBITDA (Quarterly) stood at -$44.3 million in 2021, then tumbled by 55.83% to -$69.1 million in 2022, then climbed by 8.40% to -$63.3 million in 2023, then climbed by 0.92% to -$62.7 million in 2024, then climbed by 24.74% to -$52.2 million in 2025.
  • Its last three reported values are -$52.2 million in Q3 2025, -$71.1 million for Q2 2025, and -$64.4 million during Q1 2025.